PD
SRPT icon

Point72 (DIFC)’s Sarepta Therapeutics SRPT Stock Holding History

Point72 (DIFC)’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-853
Closed -$14.6K – 1812
2025
Q2 		$14.6K Buy
+853
New +$36.4K ﹤0.01% 1267
2024
Q2 		– Sell
-22,074
Closed -$2.86M – 1877
2024
Q1 		$2.86M Buy
+22,074
New +$2.7M 0.09% 315

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Point72 (DIFC)'s SRPT Position: Q3 2025 in Review

Point72 (DIFC) sold out of Sarepta Therapeutics (SRPT) in Q3 2025, closing a stake of 853 shares — an estimated $14.6K sold.

Point72 (DIFC) first reported a position in SRPT in Q1 2024 and held it in 2 quarters. The position peaked at $2.86M in Q1 2024. 319 funds tracked by Wall St. Rank hold SRPT as of Q3 2025.

  • Point72 (DIFC) reported no remaining Sarepta Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Point72 (DIFC) sold 853 Sarepta Therapeutics shares in Q3 2025, an estimated $14.6K.
  • Point72 (DIFC) first reported a position in Sarepta Therapeutics in Q1 2024 and held it in 2 quarters.
  • Point72 (DIFC)'s Sarepta Therapeutics position peaked at $2.86M in Q1 2024.
  • 319 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2025.

Based on Point72 (DIFC)'s 13F filing for Q3 2025, filed 14 Nov 2025.